布里斯托尔·迈尔斯·斯奎布(Bristol Myers Squibbb)击败了收入估算,提高了指导,提高了股息,并与美国政府签订了药品定价协议。 Bristol Myers Squibb beat earnings estimates, raised guidance, boosted dividends, and joined drug pricing deals with the U.S. government.

Bristol Myers Squibb报告说,第三季度的收入比预期的要强,收入为16.3美元和122.2亿美元,超过估计数。 Bristol Myers Squibb reported stronger-than-expected third-quarter earnings, with $1.63 EPS and $12.22 billion in revenue, exceeding estimates. 该公司提出了其2025年全年EPS准则,并将其季度红利增加到0.63美元。 The company raised its 2025 full-year EPS guidance and increased its quarterly dividend to $0.63. 它与另外9个主要制药商一道,与美国政府签订了自愿定价协定,使美国药品价格与较低的国际价格相一致,以减少监管风险。 It joined nine other major drugmakers in voluntary pricing agreements with the U.S. government, aligning U.S. drug prices with lower international rates to reduce regulatory risk. BioNTech的免疫疗法试验取得积极进展,特别是在肝癌和肾癌方面,这促进了长期增长前景。 Positive progress in immunotherapy trials with BioNTech, particularly in liver and kidney cancer, boosted long-term growth prospects. 分析师仍然好坏参半, " 等待 " 共识评级和平均价格目标为54.62美元,尽管有些前景有所好转。 Analysts remain mixed, with a "Hold" consensus rating and a $54.62 average price target, though some raised outlooks. 机构所有权仍然很高,前沿资本和Flputnam投资管理公司最近改变了利害关系。 Institutional ownership remains high, with recent stake changes by Wedge Capital and Flputnam Investment Management.